StockNews.AI
ALKS
StockNews.AI
1 min

FORM 8.1(a) & (b) (Opening Position Disclosure)

1. Alkermes disclosed its position in the Irish Takeover Panel. 2. Avadel Pharmaceuticals is the relevant offeree in the disclosure. 3. J.P. Morgan acts as financial advisors for Alkermes. 4. Minor interests held by advisors revealed in the disclosure. 5. Disclosure date is November 5, 2025.

8m saved
Insight
Article

FAQ

Why Neutral?

The disclosure introduces no immediate value, but maintains status quo. Past event-driven disclosures have shown mixed impacts on prices.

How important is it?

The event is relevant but lacks direct impact potential, thus limiting its importance score.

Why No Impact?

The nature of the disclosure is procedural, lacking immediate financial implications. Previous similar disclosures often showed no price movement.

Related Companies

AVDL
, /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR OR AN OFFEREE 1.     KEY INFORMATION (a)  Full name of discloser: Alkermes plc (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Avadel Pharmaceuticals plc (d) Is the discloser the offeror or the offeree? OFFEROR (e)  Date position held: The latest practicable date prior to the disclosure 3 November 2025 (f)   In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" N/A 2.     INTERESTS AND SHORT POSITIONS If there are interests and positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security. Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates (Note 1) N/A All interests and all short positions should be disclosed. Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8. 3.     INTERESTS AND SHORT POSITIONS OF PERSONS ACTING         IN CONCERT WITH THE PARTY MAKING THE DISCLOSURE Details of any interests and short positions (including directors' and other employee options) of any person acting in concert with the party making the disclosure: Interests of J.P. Morgan (together with its members of staff under Rule 3.3(b)(v) of Part A of the Irish Takeover Rules), financial advisors to Alkermes plc, but, for clarity, not held on behalf of Alkermes plc: Party Class of Relevant Security Number of ordinary shares held at midnight (ET) on 3 November 2025 Percentage of total issued share capital (rounded) 55I, LLC Ordinary shares of US$0.01 each 53 0.0001 % JPMorgan Chase Bank, National Association Ordinary shares of US$0.01 each 13,500 0.0139 % TOTAL 13,553 0.0139 % Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8. Ap11 4.     OTHER INFORMATION (a)    Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" None (b)      Agreements, arrangements or understandings           relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.  None (c)     Attachments Is a Supplemental Form 8 attached?    YES/NO No Date of disclosure: 5 November 2025 Contact name: Sandy Coombs, Alkermes Telephone number: +1 781 609 6377 Public disclosures under Rule 8.1 of the Rules must be made to a Regulatory Information Service. Ap12 NOTES ON FORM 8.1(a) and (b)      See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) of Part B of the Rules.      See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.      If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted. For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel. References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022. SOURCE Alkermes plc Also from this source

Related News